New England Journal of Medicine September 16, 2021

Effect of Salt Substitution on Cardiovascular Events and Death

Bruce Neal et al.

Bottom Line

In a large cluster-randomized trial in rural China, replacing regular salt with a potassium-enriched salt substitute significantly reduced the rates of stroke, major cardiovascular events, and all-cause mortality among individuals at high cardiovascular risk.

Key Findings

1. The rate of stroke was significantly lower in the salt substitute group compared to the regular salt group (29.14 vs. 33.65 events per 1000 person-years; Rate Ratio [RR] 0.86; 95% CI, 0.77-0.96; P=0.006).

2. Major cardiovascular events occurred less frequently with the salt substitute (49.09 vs. 56.29 events per 1000 person-years; RR 0.87; 95% CI, 0.80-0.94; P<0.001).

3. Death from any cause was significantly reduced in the salt substitute group (39.28 vs. 44.61 events per 1000 person-years; RR 0.88; 95% CI, 0.82-0.95; P<0.001).

4. The rate of serious adverse events attributed to clinical hyperkalemia was not significantly higher with the salt substitute than with regular salt (3.35 vs. 3.30 events per 1000 person-years; RR 1.04; 95% CI, 0.80-1.37; P=0.76).

Study Design

Design

Cluster Randomized Trial

Open-Label

Sample

20,995

Patients

Duration

4.74 yr

Median

Setting

Rural China

Population Adults aged 60 years or older with high blood pressure, or adults of any age with a history of stroke.

Intervention Use of a potassium-enriched salt substitute (75% sodium chloride and 25% potassium chloride by mass) provided free of charge for home cooking and food preservation.

Comparator Continued use of regular salt (100% sodium chloride).

Outcome First stroke (fatal or non-fatal).

Study Limitations

• The trial utilized an open-label design, which could introduce performance or detection bias, though objective clinical endpoints like death mitigate this risk.

• The study was conducted in rural China where dietary sodium is predominantly added during home cooking; findings may be less generalizable to Western populations where processed or restaurant foods are the primary sources of sodium.

• The cohort consisted exclusively of a high-risk population (elderly, history of stroke, or hypertension); cardiovascular benefits in lower-risk or younger populations remain unconfirmed.

• Individuals with severe chronic kidney disease were not systematically evaluated or were excluded, meaning the safety profile regarding hyperkalemia cannot be generalized to patients with significant renal impairment.

Clinical Significance

The SSaSS trial provided definitive evidence that a highly affordable, scalable dietary modification—replacing regular salt with a potassium-enriched substitute—can drastically reduce the population burden of cardiovascular disease and premature death. This intervention avoids significant hyperkalemia risks in the general population, making it a compelling, low-cost public health strategy, especially in regions heavily reliant on discretionary salt for cooking.

Historical Context

Excess dietary sodium and deficient potassium intake have long been established as synergistic drivers of hypertension, a leading cause of cardiovascular morbidity worldwide. While earlier, smaller trials demonstrated that potassium-enriched salt substitutes effectively lower blood pressure, definitive randomized data on hard clinical endpoints like stroke and mortality were lacking. The massive SSaSS trial successfully bridged this gap, shifting the paradigm from observational assumptions to rigorous proof that salt substitution directly saves lives.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the physiological mechanisms by which replacing sodium with potassium lowers blood pressure, and what is the primary feared electrolyte complication of this dietary intervention?

Key Response

High dietary sodium increases blood volume and vascular reactivity, which raises blood pressure. Potassium, conversely, promotes natriuresis, induces vasodilation, and decreases renin release. The primary clinical risk to monitor is hyperkalemia, particularly in patients with impaired renal clearance or those taking certain antihypertensive medications.

Resident

A 65-year-old patient with hypertension asks if they should switch to a potassium-enriched salt substitute based on the SSaSS trial. What patient-specific factors, comorbidities, and concurrent medications must you review before safely recommending this change?

Key Response

Residents must apply trial data safely to individual patients. Before recommending a potassium-enriched salt substitute, clinicians must screen for chronic kidney disease and review the medication list for ACE inhibitors, ARBs, ARNIs, and potassium-sparing diuretics (e.g., spironolactone), as the combination can precipitate life-threatening hyperkalemia.

Fellow

The trial demonstrated significant cardiovascular and mortality benefits in rural China. How does the specific dietary context of this population impact the generalizability of the findings to Western populations, and how should this affect our dietary counseling?

Key Response

In rural China, discretionary salt (salt added during home cooking) accounts for the vast majority of daily sodium intake, making a tabletop substitute highly effective. In Western diets, approximately 70 to 80 percent of sodium is hidden in ultra-processed and restaurant foods. Fellows must recognize that simply switching tabletop salt in Western patients will yield a much smaller absolute impact unless accompanied by a reduction in processed food consumption.

Attending

Given the substantial absolute risk reduction in stroke and all-cause mortality observed with such a low-cost intervention, how can health systems pragmatically implement salt substitution at a population level while mitigating the risks of hyperkalemia in vulnerable subgroups?

Key Response

Attendings focus on systems-based practice and population health. Potassium-enriched salt is a highly cost-effective public health 'best buy.' However, system-wide implementation requires strategic workflows, such as automated EMR warnings for patients with severe CKD or on heavy RAAS blockade, combined with broad patient education to maximize benefit while ensuring safety.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The SSaSS trial utilized an open-label, cluster-randomized design at the village level. What are the major statistical and methodological challenges associated with this design, specifically concerning the intracluster correlation coefficient (ICC) and the potential for treatment contamination?

Key Response

Cluster RCTs must statistically account for the ICC to avoid underestimating the variance and falsely rejecting the null hypothesis (Type I error). Furthermore, in an open-label trial, there is a risk of contamination if control villages learn about the intervention and independently source the potassium salt. Researchers must properly power the study using a design effect multiplier and track cross-contamination.

Journal Editor

As a peer reviewer evaluating the safety endpoints of this open-label trial, what concerns might you raise regarding the ascertainment of hyperkalemia events, given the reliance on clinical reporting rather than systematic, protocol-driven laboratory monitoring?

Key Response

Editors and reviewers look for measurement and ascertainment bias. Without protocolized routine serum potassium monitoring across all participants, asymptomatic or mild-to-moderate hyperkalemia would likely be underreported. Furthermore, attributing sudden cardiac deaths accurately (e.g., distinguishing between hyperkalemia-induced arrhythmias and ischemic events) is highly challenging without systematic biochemical data.

Guideline Committee

Should current ACC/AHA and ESC/ESH hypertension guidelines be updated to provide a universal Class I recommendation for potassium-enriched salt substitutes, or do the safety profiles require conditional recommendations linked to mandatory renal function screening?

Key Response

Guideline committees must balance broad population efficacy with individual safety. While current guidelines already recommend sodium restriction and dietary potassium supplementation, upgrading potassium-enriched salt to a universal Class I recommendation is controversial. It would require logistical frameworks for mandatory CKD screening and RAAS-inhibitor monitoring to prevent iatrogenic hyperkalemia, making a blanket global recommendation difficult without geographic and systemic caveats.

Clinical Landscape

Noteworthy Related Trials

1997

TOHP II

n = 2,382 · Arch Intern Med

Tested

Dietary sodium reduction counseling

Population

Overweight adults with high-normal blood pressure

Comparator

Usual care without dietary intervention

Endpoint

Incidence of clinical hypertension

Key result: Sodium reduction interventions significantly decreased the incidence of clinical hypertension over a follow-up period of 3 to 4 years.

2001

DASH-Sodium Trial

n = 412 · NEJM

Tested

Low sodium diet combined with the DASH diet

Population

Adults with prehypertension or stage 1 hypertension

Comparator

Typical American diet with high sodium

Endpoint

Systolic blood pressure

Key result: Reducing dietary sodium intake significantly lowered blood pressure, with the greatest reductions observed when combining a low-sodium diet with the DASH diet.

2023

DECIDE-Salt Trial

n = 1,612 · Nat Med

Tested

Potassium-enriched salt substitute

Population

Older adults residing in care facilities in China

Comparator

Standard salt

Endpoint

Systolic blood pressure and major cardiovascular events

Key result: The use of a potassium-enriched salt substitute in elderly care facilities significantly lowered systolic blood pressure and reduced cardiovascular events without increasing hyperkalemia risk.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis